16 November 2022

BEXIMCO PHARMACEUTICALS LIMITED

AGM Notification

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that the forty-sixth Annual General Meeting of Shareholders (AGM) of Beximco Pharma will be held virtually on Thursday 22 December 2022 at 10.30 a.m. to transact the following business:

AGENDA

1.   To receive, consider and adopt the Audited Financial Statements of the Company for the year ended on 30 June 2022 together with reports of the Auditors and the Directors thereon.

2.   To declare 35% Cash Dividend.

3.   To elect Directors.

4.   To appoint Auditor for the year 2022-2023 and to fix their remuneration.

5.   To appoint Corporate Governance Compliance Auditor for the year 2022-2023 and to fix their remuneration.

NOTES:

(1) Shareholders whose names appear in the Share Register of the Company or in the Depository Register on the record date (i.e. 21 November 2022) will be entitled to attend the AGM and to receive the dividend.

(2) A Member entitled to attend and vote at the AGM may appoint a Proxy to attend and vote in his/her stead. The Proxy Form, duly stamped, must be deposited at the Registered office of the Company, not later than 48 hours before the time fixed for the meeting.

(3) Annual Report for the year 2021-22 will be sent through e-mail address of the Shareholders and will be available on the Company website at: www.beximcopharma.com .

(4) Shareholders will join the virtual AGM through the link https://bxpharma.bdvirtualagm.com. Shareholders will be able to submit their questions/comments and vote electronically one hour before commencement of the AGM and also during the AGM. For logging into the system, the Shareholders need to put their 16-digit Beneficial Owner (BO) ID/Folio Number and other credential as proof by visiting the said link.

(5) We encourage shareholders to login into the system prior to the meeting. Please allow ample time to login and establish your connectivity. For any IT related guidance, shareholders may contact vide email: [email protected]t or [email protected] .

For further information please visit www.beximcopharma.com or enquire to:

Beximco Pharma

Nazmul Hassan MP, Managing Director

Tel: +880 2 58611001, Ext.20080

S M Rabbur Reza, Chief Operating Officer

Tel: +880 2 58611001, Ext.20111

Mohammad Ali Nawaz, Chief Financial Officer

Tel: +880 2 58611001, Ext.20030

Jamal Ahmed Choudhury, Director, Accounts & Finance

Tel: +880 2 58611001, Ext.20022

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott

Tel: +44 (0) 20 3368 3551 / 3555

SP Angel Corporate Finance LLP (Broker)

Vadim Alexandre / Abigail Wayne

Tel: +44 (0) 20 3470 0470

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0) 20 3727 1000

Notes to Editors

About Beximco Pharmaceuticals Limited

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 5500 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.